The trials will test the ability of the firm's fluorine-18 labeled PET tracer to detect FAP-expressing tumor cells in ...

DULLES, Va., Dec. 29, 2025 /PRNewswire/ -- SOFIE Biosciences, an established U.S. manufacturer and developer of radiopharmaceuticals, today announced that the first patient has been dosed in one of ...

SOFIE Biosciences, an established US manufacturer and developer of radiopharmaceuticals, announced that the first patient has been dosed in one of its two phase 3 clinical trials evaluating ...

Increased Research Activity: A significant surge in FAP-related publications was observed starting in 2019, with China, the USA, and Germany leading in productivity and international collaboration.